Reversion of Somatic Mutations of the Respiratory Syncytial Virus-Specific Human Monoclonal Antibody Fab19 Reveal a Direct Relationship between Association Rate and Neutralizing Potency.

Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232
The Journal of Immunology (Impact Factor: 5.36). 03/2013; DOI: 10.4049/jimmunol.1202964
Source: PubMed

ABSTRACT The role of affinity in determining neutralizing potency of mAbs directed against viruses is not well understood. We investigated the kinetic, structural, and functional advantage conferred by individual naturally occurring somatic mutations in the Ab H chain V region of Fab19, a well-described neutralizing human mAb directed to respiratory syncytial virus. Comparison of the affinity-matured Ab Fab19 with recombinant Fab19 Abs that were variants containing reverted amino acids from the inferred unmutated ancestor sequence revealed the molecular basis for affinity maturation of this Ab. Enhanced binding was achieved through mutations in the third H chain CDR (HCDR3) that conferred a markedly faster on-rate and a desirable increase in antiviral neutralizing activity. In contrast, most somatic mutations in the HCDR1 and HCDR2 regions did not significantly enhance Ag binding or antiviral activity. We observed a direct relationship between the measured association rate (Kon) for F protein and antiviral activity. Modeling studies of the structure of the Ag-Ab complex suggested the HCDR3 loop interacts with the antigenic site A surface loop of the respiratory syncytial virus F protein, previously shown to contain the epitope for this Ab by experimentation. These studies define a direct relationship of affinity and neutralizing activity for a viral glycoprotein-specific human mAb.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Immune-mediated lung injury is a hallmark of RSV lower respiratory tract illness. STAT4 plays a critical role in CD4+ Th1 lineage differentiation and IFN-γ protein expression by CD4+ T cells. As CD4+ Th1 differentiation is associated with negative regulation of CD4+ Th2 and Th17 differentiation, we hypothesized that RSV infection of STAT4(-/-) mice would result in enhanced lung Th2 and Th17 inflammation and impaired lung Th1 inflammation compared to WT mice. We performed primary and secondary RSV challenge in WT and STAT4(-/-) mice, and used STAT1(-/-) mice as a primary challenge positive control for the development of RSV-specific lung Th2 and Th17 inflammation. Primary RSV challenge of STAT4(-/-) mice resulted in decreased T-bet and IFN-γ expression in CD4+ T cells compared to WT mice. Lung Th2 and Th17 inflammation did not develop in primary RSV-challenged STAT4(-/-) mice. Decreased IFN-γ expression by NK cells, CD4+ T cells, and CD8+ T cells was associated with attenuated weight loss and enhanced viral clearance with primary challenge in STAT4(-/-) mice compared to WT mice. Following secondary challenge, WT and STAT4(-/-) mice also did not develop lung Th2 or Th17 inflammation. In contrast to primary challenge, secondary RSV challenge of STAT4(-/-) mice resulted in enhanced weight loss, increased lung IFN-γ expression, and an increased lung RSV-specific CD8+ T cell response compared to WT mice. These data demonstrate that STAT4 regulates the RSV-specific CD8+ T cell response to secondary infection, but does not independently regulate lung Th2 or Th17 immune responses to RSV challenge.
    Journal of Virology 06/2014; · 4.65 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The process of antibody ontogeny typically improves affinity, on-rate, and thermostability, narrows polyspecificity, and rigidifies the combining site to the conformer optimal for binding from the broader ensemble accessible to the precursor. However, many broadly-neutralizing anti-HIV antibodies incorporate unusual structural elements and recognition specificities or properties that often lead to autoreactivity. The ontogeny of 4E10, an autoreactive antibody with unexpected combining site flexibility, was delineated through structural and biophysical comparisons of the mature antibody with multiple potential precursors. 4E10 gained affinity primarily by off-rate enhancement through a small number of mutations to a highly conserved recognition surface. Controverting the conventional paradigm, the combining site gained flexibility and autoreactivity during ontogeny, while losing thermostability, though polyspecificity was unaffected. Details of the recognition mechanism, including inferred global effects due to 4E10 binding, suggest that neutralization by 4E10 may involve mechanisms beyond simply binding, also requiring the ability of the antibody to induce conformational changes distant from its binding site. 4E10 is, therefore, unlikely to be re-elicited by conventional vaccination strategies.
    PLoS Pathogens 09/2014; 10(9):e1004403. · 8.14 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The role of binding kinetics in determining neutralizing potency for antiviral antibodies is poorly understood. While it is believed that increased steady-state affinity correlates positively with increased virus-neutralizing activity, the relationship between association or dissociation rate and neutralization potency is unclear. We investigated the effect of naturally-occurring antibody resistance mutations in the RSV F protein on the kinetics of binding to palivizumab. Escape from palivizumab-mediated neutralization of RSV occurred with reduced association rate (Kon) for binding to RSV F protein, while alteration of dissociation rate (Koff) did not significantly affect neutralizing activity. Interestingly, linkage of reduced Kon with reduced potency mirrored the effect of increased Kon found in a high-affinity enhanced potency palivizumab variant (motavizumab). These data suggest that association rate is the dominant factor driving neutralization potency for antibodies to RSV F protein antigenic site A and determines the potency of antibody somatic variants or efficiency of escape of viral glycoprotein variants.
    Virology 04/2014; s 454–455:139–144. · 3.28 Impact Factor